Pfizer Raises Full-Year Revenue and Earnings Guidance — Company Talk

What happened

Pfizer raised its full-year 2026 revenue guidance by $1.5 billion at the midpoint to between $62 billion and $64.0 billion after strong third-quarter performance, and lifted its adjusted diluted EPS outlook to $2.95 to $3.05.

Confirmed

Global impact / market context

Higher guidance means Pfizer expects more sales and profit than before, which can support the dividend and fund research. Growth in cancer and rare-disease drugs is replacing shrinking COVID-19 sales, so investors can judge whether the company is replacing lost revenue.

Analyst inference

The forecast includes a $650 million charge for a licensing deal with Innovent Biologics, a one-time cost that lowers reported profit. Investors will compare Pfizer with other drugmakers facing falling COVID-19 demand and watch whether new products keep growing fast enough.

Analyst inference

What to watch

1. Pfizer said third-quarter operational revenue grew 7% excluding Comirnaty and Paxlovid, with double-digit growth in oncology and rare disease treatments, so these new products are the main growth engine. Confirmed
2. Watch for detail on the Innovent Biologics licensing deal, including what medicines it covers, because the $650 million charge reduces near-term profit and its payoff is not yet described. Proposed
3. Track whether COVID-19 vaccine and treatment sales keep falling and whether oncology and rare-disease revenue grows fast enough to offset that decline, since this decides if the raised guidance holds. Analyst inference

Evidence

• Original source link unavailable